Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

43.62 -0.93 (-2.09%)
Streaming Delayed Price Updated: 11:45 AM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Latest Analyst Ratings for Travere Therapeutics ↗
 
Via Benzinga
News headline image
Could an FDA Approval Send This Stock Flying? ↗
Is now the time to load up on this struggling stock? 
Via The Motley Fool
News headline image
Travere Therapeutics's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Why Travere Therapeutics Stock Bolted Higher This Week ↗
A high-value regulatory approval lit a fire underneath the biotech's shares this week. 
Via The Motley Fool
News headline image
Travere Therapeutics to Report First Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Additional Data From Travere Therapeutics' Kidney Disease Candidate Reinforce Efficacy, Supporting Ongoing Launch ↗
 
Via Benzinga
News headline image
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control 
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Up-and-Coming Growth Stocks to Buy Right Now ↗
These companies are small now but could grow much larger over time. 
Via The Motley Fool
News headline image
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing ↗
The high-flyers have soared to new heights and further gains could be up ahead. 
Via The Motley Fool
News headline image
What 10 Analyst Ratings Have To Say About Travere Therapeutics ↗
 
Via Benzinga
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023 ↗
 
Via Benzinga
News headline image
Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Announces Proposed Public Offering of Common Stock
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
News headline image
Earnings Scheduled For February 23, 2023 ↗
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗
 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.